INTRODUCTION 21
Many isoflavones act as phytoestrogens due to de fact that these compounds present 22 similarities in chemical structure and properties to endogenous steroids (e.g. 17-β-23 estradiol). The most important dietary sources of isoflavones are soy beans and soy 24 foods. The soy isoflavones aglycones daidzein (4',7-dihydroxyisoflavone), equol (4',7-25 dihydroxy-3,4-dihydroisoflavone), and genistein (4',5,7-trihydroxyisoflavone) (See 26 Figure 1 ) display a number of biological activities which have been related to lower 27 occurrences of cardiovascular diseases, osteoporosis, hormone-dependent cancers, 28 adverse menopausal manifestations, and age-related cognitive decline.
1, 2

29
In order to evaluate the importance of isoflavones on human health, it is necessary 30 to have a better understanding of the bioavailability and pharmacokinetics of these 31 compounds. Isoflavone disposition follows several deconjugation and conjugation steps. 32
Soy and unfermented soy food isoflavones are mainly found as glycosides (e.g. daidzin, 33 genistin, and glycitin), they display high hydrophilicity and molecular weights, and are 34 the object of a number of metabolic biotransformations. Firstly, gut bacterial β-35 glucosidases 3 and the gastric acidic pH carry out the hydrolysis of the sugar moiety. 36
This facilitates the absorption process 4, 5 that takes place by passive diffusion in the 37 upper small intestine.
6 Then, the intestinal 7 and hepatic 8 phase II enzymes UDP-38 glucuronyl transferases and PAPS-sulfotransferases carry out the corresponding 39 conjugation with glucuronic acid and sulphate. The excretion of these conjugates can be 40 both renal and biliary, the later undergoing enterohepatic recirculation, which leads to 41 4 activities 10 and some of them, such as sulphates, have been reported to have higher 46 activities than the corresponding aglycones.
11
47
Whereas daidzein and genistein are present in soy foods, equol is a metabolite of 48 daidzein whose production depends upon the individual gut microflora 12 and only 30-49 50% of the adult Caucasian population is able to produce it.
1 Unlike daidzein or 50 genistein, equol presents a stereogenic centre at C-3, and therefore different 51 enantiomeric forms exist. In humans, (S)-equol is the only enantiomer which is 52 produced by intestinal bacterial flora.
13 This fact is of clinical relevance since both 53 enantiomers have different activities; (S)-equol, but no (R)-equol, displays high affinity 54 for the oestrogen receptor beta (ERβ) and its activity is even higher than that of 55 estradiol.
13
56
Because of the beneficial health effects that soy isoflavones may provide to humans, 57 several brands of isoflavone extracts have been commercialized over the last decades. 58
However, there is little information concerning these preparations with respect to their 59 specific isoflavone profile and quantity. Differences in bioavailability and 60 pharmacokinetics may have an impact on isoflavone biological and pharmacological 61 activities. 62
A number of analytical methods have been developed to detect and quantify 63 isoflavone concentrations in biological fluids (plasma, serum, and urine). The most 64 commonly used include gas chromatography coupled to mass spectrometry (GC/MS), 4, 17 At present, LC/MS/MS is the most commonly employed analytical 68 technique due to its high sensitivity and selectivity. 69 6 each substance in 10 mL of methanol. Working solutions were prepared by further 94 diluting the starting solutions and were kept in dark flasks at -20 ºC. 95
Instrumentation: LC/MS/MS conditions 96
Identification and quantification analysis was performed using an Agilent 1200 97 series HPLC system (Agilent technologies) coupled to a triple quadrupole (6410 Triple  98 Quad LC/MS; Agilent) mass spectrometer with an electrospray interface. Nitrogen was 99 employed as a drying and nebulizing gas. A capillary voltage of 4 kV in negative 100 ionization mode was used and the source temperature was set to 325 ºC. 101
The liquid chromatographic separation of daidzein, equol and genistein was 102 performed at 40 ºC on an Acquity UPLC ® BEH C 18 column (100 mm x 3.0 mm i.d., 1.7 103 µm particle size) (Waters Corporation). The mobile phase was an isocratic solvent 104 system consisting of 0.01% ammonium acetate at pH 5 and methanol (40:60, v/v) at a 105 flow rate of 0.3 mL/min. Injection volume was 10 µL. The total run time was 5 min per 106 sample. All compounds were monitored in negative ionization using the multiple 107 reaction mode. Daidzein and genistein were quantified by comparing their peak area 108 ratios with daidzein-d 6 (IS1) whereas equol was quantified using equol-d 4 as internal 109 standard (IS2). Due to the chemical structure similarities between daidzein and 110 genistein, daidzein-d 6 was used as the internal standard of genistein. 111
Sample preparation 112
Firstly, 1 mL aliquot of plasma sample was transferred into a glass tube and 113 spiked with 30 µL of IS1 solution (containing daidzein-d 6 10 µg/mL) and 10 µL of IS2 114 (containing 10 µg/mL of equol-d 4 ). Approximately 3000 units of β-glucuronidase H1 (2 115 mg/mL, in 0.1 M sodium citrate buffer, pH = 5) were added and sample was incubated 116 at 37 ºC for 16 hours in a shaking water bath. Hydrolysis time could be reduced to 1 117 hour if the temperature of the water bath was increased to 55 ºC. 118 7 After cooling to room temperature, 1 mL of 4% H 3 PO 4 was added and all the 119 tubes were centrifuged at 3500 rpm for 5 minutes. They were then submitted to a solid-120 phase extraction (SPE) procedure using Oasis ® MAX cartridges (3cc, 60-mg; Waters 121
Corporation, Dublin, Ireland). Cartridges were conditioned with 2 mL of methanol and 122 equilibrated with 2 mL of water. After sample loading, interferences were washed away 123 with 2 mL of 5% NH 4 OH and 2 mL of 2% HCOOH containing 10% methanol. The 124 compounds of interest were then eluted with 2 mL of a solution of methanol containing 125 2% HCOOH. After the evaporation of the solvent (<29 ºC, <10 psi), analytes were 126 reconstituted in 100 µL of CH 3 COONH 4 0.01%, pH=5/MeOH (50/50). Finally, samples 127 were centrifuged at 12,000 rpm for 10 min at 4 ºC and supernatants analyzed by 128 HPLC/MS/MS. 129
Method validation 130
Calibration curves and linearity 131
Calibration standards of daidzein, equol, and genistein were prepared each 132 analysis day and consisted of two replicates at 6 different concentrations (5, 50, 200, 133 500, 750, and 1000 ng/mL). Calibration curves were prepared by adding the appropriate 134 volume of working solutions, evaporating the solvent under N 2 (25 ºC, 10 psi), and 135 adding 1 mL of isoflavone-free plasma. Calibration curves with their corresponding 136 slope (s), intercept and correlation coefficient (r) were calculated by weighting (1/x) 137 least-squares linear regression of the peak area ratio (analyte/IS) versus the 138 concentration of the standards. The method was considered linear if the coefficient of 139 determination was greater than 0.99. 140
Intra-assay accuracy and precision 141
In order to evaluate the precision and accuracy of the method, quality control 142 (QC) samples were prepared by spiking known amounts of the analytes to isoflavone-143 8 free human plasma in order to achieve final concentrations of 5 (lower limit of 144 quantification; LLOQ), 10 (low QC), 100 (medium QC), and 800 (high QC) ng/mL of 145 daidzein, equol, and genistein. Inter-assay accuracy and precision 159
Inter-assay accuracy and inter-assay precision were calculated as described for 160 intra-assay accuracy and precision with data obtained during three validation assays that 161 took place during three different days. 162
Limit of detection (LOD) 163
The LOD was calculated using the standard deviations (SD) of the obtained 164 concentrations from five replicates of the LLOQ (5 ng/mL) and the slope (s) of the 165 calibration curve, according to the following formula: LOD = 3.3 * (SD/s). 166
Additionally, at the estimated LOD of the surrogated analytes, it was confirmed that the 167 LOD was at least 3 times the signal to noise ratio of a blank plasma sample. 
Lower limit of quantification (LLOQ) 169
The LLOQ was the lowest concentration calibrator experimentally tested that 170 presented acceptable accuracy (80-120%) and precision (±20%). 171
Extraction recovery 172
The extraction process recovery was evaluated by comparing the responses of a 173 mixture of standards with and without extraction. For this purpose, six different sources 174 of isoflavone-free plasma were spiked at a low (5 ng/mL) and high (800 ng/mL) level of 175 concentration. The extraction recovery was calculated as the quotient of response of 176 standard solutions spiked into plasma before extraction (with standard) and the response 177 of standard solutions spiked into plasma after extraction. Results are expressed as a 178
percentage. 179
Matrix effect 180
In a similar way, the matrix effect was analysed using six different batches of 181 isoflavone-free plasma at two concentrations (5 and 800 ng/mL). test, urinalysis, and 12-lead ECG. Moreover, during the three days prior to the 210 intervention, they were asked to follow a diet free from daidzin, genistin, daidzein and 211 genistein (including soybeans and soy foods). A list of isoflavone rich food was 212 provided. Alcoholic beverages were not permitted 72 hours prior to each intervention. 213
Commercial isoflavone preparations 214
The soy isoflavone preparations used in this study were two commercially 215 Fitoladius® contains 60 mg of soybean seed extract (Glycine max), with 24 mg (40%) 221 of total isoflavone content, the specific amount of each isoflavone is not, however, 222 described in the information leaflet. 223
Drug administration and sample collection 224
The treatment with Super Absorbable Soy Isoflavones® consisted of a single 225 oral intake of 2 capsules (total dose: 108 mg isoflavones), whereas that of Fitoladius® 226 was 4 capsules (total dose: 96 mg isoflavones). The objective of this approach was to 227 compensate the previously mentioned differences in isoflavone content of the extracts, 228 as provided by the manufacturers (54 mg vs 24 mg in each capsule). On the intervention 229 days, each volunteer received an oral dose of a soy isoflavone extract. In order to avoid 230 batch-to-batch differences in isoflavone composition, all the capsules of each treatment 231
were from the same batch number. Moreover, as explained bellow, the composition of 232 five different capsules corresponding to that batch was analysed. 233
Subjects arrived at the clinical trial unit on the intervention day at 07:45 a.m. 234 after an overnight fast. Spot urine samples were collected for drug testing (opiates, 235 cocaine, amphetamines, and cannabis) by a rapid test device (Instant-View®, Alpha 236 Scientific Designs, Inc, Poway, CA, USA). In addition, a breath ethanol test was also 237 conducted. A positive screen test was considered an exclusion criterion. Intervention 238 days were separated by at least a 3-day washout period. An indwelling intravenous 239 catheter inserted into a subcutaneous vein in the forearm of the non-dominant arm and 240 blood samples were collected at baseline and 1, 3, 5, 6, 7, 8, 9, 12, and 24h after 241 treatment administration. Blood was collected into 10 mL tubes containing EDTA and 242 12 centrifuged (3000 rpm, 10 min, 4 ºC). The plasma samples were then separated and 243 frozen at -20 ºC until analysis. 244
Quantification of isoflavones in soy extract capsules 245
Although the treatment dosages (based on the information provided by the 246 manufacturers) were designed to contain similar doses of isoflavones, it was expected 247 that there would be differences in the plasmatic concentrations of specific isoflavones 248 (e.g. genistein and daidzein) as in the Fitoladius preparation their composition was not 249 declared. Consequently, it was necessary to measure the exact content of isoflavones of 250 the capsules. The isoflavone content of the preparations [aglycones (daidzein and 251 genistein) and β-glycoside conjugates (daidzin and genistin)] was determined by 252 LC/MS/MS as follows: a sample stock solution (1 mg/mL) from each was prepared by 253 dissolving 10.0 mg of capsule content in 10 mL of methanol and sonicating it for 5 254 minutes to achieve complete dissolution. Analysis solutions of 100 µg/mL and 10 255 µg/mL were prepared by further diluting the stock solution. One milliliter of the 256 analysis solution, spiked with 30 µL of a solution containing daidzein-d 6 10 µg/mL, was 257 subjected to the previously described solid phase extraction procedure. Ten µL of the 258 solution were injected in the LC/MS/MS system. Each determination was performed by 259 analysing five different capsules corresponding to the same batch used for the study. 260
The separation of the compounds was carried out using the same conditions described 261 earlier. The aglycones were quantified directly whereas the glycosides were quantified 262 indirectly after hydrolysis. Calculations were based on the response factor of the ratio of 263 the analyte versus internal standard. 264
Pharmacokinetic analysis 265
The maximum plasma concentration (C max ) and the time to reach C max (t max ) were 266 determined from the curves constructed by plotting the plasma concentrations over 267 13 time. The terminal slope (k e ) of the concentration-time curve was determined by log-268 linear regression using at least the last three points. 
RESULTS AND DISCUSSION 285
Method development and optimization 286
Optimization of MS/MS conditions 287
In order to evaluate ionization sources and multiple reaction monitoring (MRM) 288 transitions, the three most intense fragments of each compound (daidzein, daidzein-d 6 , 289 equol, equol-d 4 and genistein) were selected using pure standards at 10 µg/mL in 290 negative ion mode. To further improve MRM conditions, the effect of gas temperature, 291 and collision and fragmentor energies were investigated over the range of 300-350 ºC, 292 Table 1 . 295
Optimization of LC conditions 296
Different chromatographic columns were tested to study their effect on peak 297 shapes and separation efficiency. Depending on the polarity of the stationary phase 298 these included: cyanopropylsilyl-(CN; Acquity UPLC ® HSS cyano 1.8 µm, 2.1x50 299 mm), n-octylsilyl-(C 8 ; Zorbax SB-C 8 RRHT 1.8 µm, 2.1x100 mm), phenylhexylsilyl-300 (Acquity UPLC ® BEH Phenyl 1.7 µm 2.1x100 mm), and n-octadecylsilyl-(C 18 ; 301 Acquity UPLC ® BEH C 18 1.7 µm, 3.0x100 mm) moieties on silica. After having 302 compared the four chromatographic columns, the latter was chosen to continue with the 303 optimization of the methodology because it provided the best separation with good 304 resolution for equol, daidzein, and genistein. 305
Chromatographic separation of the analytes was optimized by evaluating four 306 mobile phases (0.1% HCOOH, 0.01% NH 4 CH 3 COO, acetonitrile, and methanol). A 307 rapid separation (<5 min) of the three compounds of interest was achieved using an 308 isocratic solvent system consisting of 0.01% ammonium acetate at pH 5 and methanol 309 (40:60, v/v) (Figure 2) . 310
Optimization of the solid phase extraction procedure 311
To optimize the extraction of the analytes of interest from plasma, several solid-312 phase extraction procedures were evaluated by spiking known amounts of the analytes, 313 and calculating the corresponding recoveries and matrix effect. Five different cartridges 314 were evaluated. These included Oasis ® MCX, WAX, MAX, WCX, and HLB (Waters 315 corporation). The highest recovery of the analytes was achieved when MAX cartridges 316 were used, although a marked matrix effect was present. In order to avoid the co-eluting 317 matrix components affecting the ionization efficiency of the analytes, different washes 318 were evaluated. Neither basic washes with 5% NH 4 OH, nor additional washing steps 319 using methanol, improved the matrix effect. However, when acidic washes were studied 320 using mixtures of methanol and 2% formic acid, the matrix effect was enhanced. The 321 best results were obtained when 2% HCOOH and methanol (90:10; v/v) were 322 employed. 323
Optimization of the hydrolysis 324
The efficacy of different enzymes to hydrolyze the sulphate and glucuronic acid 325 moieties present in the phase II conjugates of equol, genistein, and daidzein was 326 The best results were obtained when the samples were treated with 3,000 units 334 of β-Glucuronidase H-1 from Helix pomatia at pH = 5 after an incubation at 37 ºC for 335 16 hours. Interestingly, similar results were achieved when hydrolysis time was reduced 336 to 1 hour and the temperature of the water was increased to 55 ºC. This glucuronidase 337 has been previously used in the analysis of soy isoflavones [18] [19] [20] [21] . 338
Under the conditions described above, the percentage of hydrolysis of daidzein-339 4-sulphate, daidzein-7-β-D-glucuronide, and daidzein-7-β-D-glucuronide-4-sulphate 340 was higher than 95%. With greater amounts of β-glucuronidase (5,000 units), the 341 percentage of hydrolysis was constant although the matrix effect increased. Whilst the 342 Page 15 of 35
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Journal of Agricultural and Food Chemistry hydrolysis of most of the metabolites was successful, none of the studied conditions was 343 able to hydrolyze equol-4-sulphate, the yield being below 5%. Studies regarding equol 344 metabolism in humans, monkeys, and rats have reported that sulphation is a minor 345 metabolic pathway of this compound.
22 As described below, despite having detected 346 equol in plasma samples from three volunteers, the pharmacokinetics of this metabolite 347
has not been evaluated in this report. 348
It is worth noting that a total quantification of isoflavones was chosen due to the 349 large number of isoflavone glucuronide and sulphate metabolites conjugates that have 350 been described to date in humans 16 and animals. 9 Although some of these conjugates are 351 commercially available, the lack of an appropriate commercially available IS of all of 352 them for their proper quantification was a major limitation for their inclusion in the 353 bioavailability study. For this reason, a total quantification of the isoflavones was 354 performed following sample hydrolysis. To do so, four different representative 355 metabolites presenting glucuronides and/or sulphate moieties were custom synthesized. 356
The hydrolysis procedure was optimized in order to assure that the conditions used were 357 able to release the aglycones. Finally, the quantification of total isoflavones was 358 performed in real plasma samples using the optimized hydrolysis procedure 359 Intra-and inter-day accuracies presented acceptable % relative error for the three 368 compounds, and the intra-and inter-day precision were constantly below 15% RSD 369 (Supplementary Table 1) . 370
Method validation
The LOD for daidzein, equol, and genistein were 0.6, 0.9, and 1.0 ng/mL, 371 respectively. The LLOQ for these three isoflavones was 5 ng/mL. 372
The % matrix effect for daidzein, equol, genistein, and their corresponding IS 373 assessed at 5 and 800 ng/mL, indicate that ion suppression was lower than 17.2% and 374 ion enhancement was not higher than 17.8%. The extraction recoveries were between 375 77.5 and 86% ( Table 2) . 376
No significant degradation of daidzein, equol, and genistein in human plasma 377 took place after long-term storage at -20 ºC during the analysis period. The low and 378 high QC samples presented acceptable values (± 15% the nominal values) during at 379 least 8 months after their preparation. 380
Quantification of isoflavones in soy preparations 381
Supplementary Table 2 shows the quantification of daidzein, genistein, daidzin, 382 and genistin present in one capsule of the commercially available soy preparations 383 studied. Both commercial sources presented predominantly β-glycoside conjugates 384 (98%), the free forms representing only a small percentage of the isoflavone content 385 (approximately 2%). In Fitoladius®, daidzin was found to account for 37.4% of the total 386 isoflavone weight, whereas genistin was the most abundant isoflavone, representing 387 60.3%. On the other hand, Super Absorbable Soy Isoflavones® had almost the same 388 amount of daidzin as genistin (50.0% and 48.1%, respectively). The aglycones were 389 only present in very low amounts, being daidzein at a higher proportion (1.1-1.7%) than 390 genistein (0.6-0.7%). The total isoflavone content of Fitoladius® was found to exactly 391 match the content provided in the information pamphlet (23.8 mg vs 24 mg). In the case 392
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Journal of Agricultural and Food Chemistry of Soy Isoflavones®, the content of genistin and genistein was 1.2-fold that described 393 by the manufacturer (35.5 mg vs 28 mg). As for daidzein and daidzin concerns, the 394 amount quantified (34.5 mg) was 1.6-fold that given in the specifications (22 mg). This 395 fact is of relevance, since the dosages administered to the volunteers were based on the 396 information provided by the manufacturer. In order to compensate for these differences, 397 the pharmacokinetic parameters were normalised by the dose administered. To do so, 398 each plasmatic concentration value (derived from the calibration curve) was divided by 399 the amount administered of the corresponding isoflavone. 400
The other constituents present in the soy preparations were excipients. In the case of 401
Fitoladius®, and according to the manufacturer, these are primrose oil, glyceryl 402 monostearate, glycerol, cuprosodic chlorophyll, gelatine, titanium dioxide and purified 403
water. In the case of Super-Absorbable Soy Isoflavones®, these are ascorbyl palmitate 404 and vegetable cellulose. The analysis of these excipients is beyond the scope of this 405
paper. 406
Quantification of isoflavones in human plasma samples 407
Equol 408
Only three of the twelve volunteers were found to be equol producers. In these 409 volunteers, equol concentrations started to increase between 5 and 6 hours after the 410 treatment administration and could still be detected at 24 h. Due to this fact, the 411 pharmacokinetics of this metabolite is not evaluated in this report. 412
Daidzein and genistein pharmacokinetics 413
Time-course plasma concentrations of total genistein and daidzein are shown in 414 course plasma concentrations suggests an enterohepatic circulation, which is 419 characteristic of these compounds (Figure 3) . 6, 25 To a lesser extent, the small 420 percentages of aglycones present in the soy extracts could also contribute to this 421 pharmacokinetic profile, as the free forms are absorbed faster than the glycosides.
26
422
The pharmacokinetic parameters studied (AUC 0-24h , C max , AUC 0-24h /Dose, 423 C max /Dose, t max , t 1/2 , k e ) are reported in Table 3 . As shown using the AUC 0-24h /Dose 424 ratio, the bioavailability of daidzein and genistein was higher after the intake of 425 Fitoladius® (p<0.05 and p<0.001, respectively), compared to Super Absorbable Soy 426 Isoflavones® (Figure 3) . 427
Cmax/Dose values of genistein also differed significantly between treatments 428 (p<0.001). After the intake of Fitoladius® these values were higher than the other 429 studied preparation. No differences were observed in t max , t 1/2 , k e . 430
Several factors can influence the metabolism and bioavailability of isoflavones in 431 humans. These include age, ethnic background, dietary habits, food matrix, intestinal 432 microflora, intestinal transit time, previous exposure to isoflavones, and glycosidase 433 production.
27, 28 In our case, the differences in bioavailability suggest that the 434 excipients/matrix in which these products are present may play an important role in the 435 absorption process, which could have a direct impact on the bioavailability of soy 436
isoflavones. This fact would explain the different pharmacokinetic profile observed 437 between treatments when the same 12 volunteers received two different soy extracts. 438
Our study has strengths and limitations. One of the strengths is the crossover design, 439 which allowed the same participants to be included in the different treatments, thus, 440 minimising interferences with other confounder variables. Another strength lies in the 441 fact of including both genders among the participants, thus, having a better 442 20 representation of the overall population. One limitation of our study is that, due to the 443 available commercial sources of the soy extracts, the isoflavone composition of the two 444 tested products differed significantly. Consequently, the participants did not receive 445 exactly the same doses in the two soy isoflavone extracts. In order to minimise these 446 differences, the exact amount of each isoflavone was firstly analysed, and normalisation 447 by the dose administered was performed prior to pharmacokinetic analyses. 448
In conclusion, in the present study we developed a LC/MS/MS method based on an 449 enzymatic hydrolysis with β-glucuronidase H1 followed by SPE procedure using 450
Oasis® MAX cartridges. The analytical method was successfully validated following 451 the European Medicines Agency guidelines on Bioanalytical Method Validation. This 452 methodology presents a good recovery of the analytes, very low matrix effects, a rapid 453 chromatographic separation and high sensitivity. The limits of detection for daidzein, 454 equol, and genistein in 1 mL of plasma sample were 0.6, 0.9 and 1.0 ng/mL, 455 respectively. Once the method was validated, a crossover, randomized, bioavailability 456 study was performed. The method was then applied to the plasma samples of the 12 457 volunteers. The pharmacokinetic profile of daidzein and genistein was studied. 458
After having been normalized, Fitoladius® presented higher bioavailability and 459 achieved higher Cmax values than Super Absorbable Soy Isoflavones® for daidzein and 460 genistein. As the other pharmacokinetic parameters were similar between both 461 treatments, we suggest that these differences in bioavailability come from the 462 matrix/excipients present in the capsules of the isoflavone extracts. 463
The preparations studied are over-the-counter dietetic preparations, they do not 464 require medical prescription, and some of them can be purchased on the internet. Thus, 465 the regulation of these products is not as strict as that applied to prescription drugs. 
